Bladder cancer (BC) is the sixth most common cancer in men. Moreover, chemotherapy for BC leads to various side effects. Metformin is known to induce apoptosis in vitro in many types of cancer. Furthermore, it has feasibility as a drug repositioning used for the treatment of cancer. The molecular mechanism of metformin mediating apoptosis in BC is still unclear. In this study, we showed that metformin stimulated the caspase-dependent apoptotic signaling pathway in T24 cells, a human BC cell line. Moreover, the induced apoptosis was partially inhibited by a general caspase inhibitor, z-VAD-fmk, which suggested that metformin-induced apoptosis in T24 cells is partially caspase-independent. Notably, we observed the nuclear translocation of apoptosis-inducing factors (AIFs) in metformin-promoted apoptosis, which is a typical characteristic of the caspase-independent apoptotic pathway. In addition, we found that metformin-mediated apoptosis occurred via degradation of the cellular FADD-like interleukin-1β-converting enzyme inhibitory protein (c-FLIPL) by facilitating ubiquitin/proteasome-mediated c-FLIPL degradation. Furthermore, treatment with the reactive oxygen species scavenger N-acetylcysteine, failed to suppress metformin-induced apoptosis and c-FLIPL protein degradation in metformin-treated T24 cells. In conclusion, these results indicate that metformin-induced apoptosis was mediated through AIF-promoted caspase-independent pathways as well as caspase-dependent pathways in T24 cells. As such, metformin could be used as a possible apoptotic agent for the treatment of BC. Anti-Cancer Drugs 31: 655–662 Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc.

Keywords: apoptosis, apoptosis-inducing factor, bladder cancer, c-FLIPL, metformin

Introduction
Bladder cancer (BC) is associated with several risk factors, such as smoking, bladder infection, radiation therapy and exposure to specific chemicals [1,2]. Moreover, BC is a common cancer worldwide, with a higher incidence for men than for women [3]. However, current treatments for BC, such as surgery, radiation and chemotherapy are associated with various side effects. Therefore, it is necessary to find a more efficient chemotherapeutic agent for BC.

Metformin has feasibility as a drug repositioning used for the treatment of cancer [4]. Its mechanism involves the degradation of blood glucose via activation of the AMP-activated protein kinase (AMPK). The AMPK regulates ATP and NADPH levels and therefore regulates cell survival and death [5,6]. The activation of AMPK occurs via suppression of mammalian target of rapamycin signaling [7]. Thus, metformin, like other AMPK modulators, is considered an important anti-cancer agent in establishing novel therapeutic strategies for human cancers [8,9]. Previous studies have reported that metformin could prevent cancer cell growth and proliferation [10,11]. It was also shown to activate apoptotic pathways in several kinds of cancer cells, such as colorectal cancer, cervical cancer, thyroid cancer, bile duct cancer, lung cancer, megakaryoblastic cells and glioma cells via the signal transducer and activator of transcription 3 and transforming growth factor-β/SMAD signaling pathways, cyclin D1 and p53 expression, endoplasmic reticulum stress, insulin-like growth factor (IGF) 1 receptor pathways, invasion, ERK1/2, JNK or PI3K/Akt pathway and migration, respectively [12–18]. Nevertheless, the underlying molecular mechanisms of its anti-cancer effects have not been elucidated in human BC T24 cells. As such, the purpose of this study was to verify the anti-cancer properties of metformin in BC T24 cells and explain its underlying molecular mechanism.

Apoptosis-inducing factor (AIF) is associated with control of the programmed cell death process that is initiated by the mitochondrial signaling pathway also known as the intrinsic pathway [19]. Moreover, the nuclear translocation of AIF is involved in the caspase-independent pathway. Many kinds of cancer cells have mutations in the major apoptotic genes. Furthermore, cancer cells have a resistance to existing drugs, which poses an obstacle in the use of chemotherapeutics for cancer treatment. Thus, the activation of the caspase-independent apoptosis
signaling pathway has become an aggressive approach to kill cancer cells [20–24].

In the present study, we showed that metformin induces apoptosis in BC T24 cells by activating both caspase-dependent and caspase-independent apoptotic pathways via nuclear translocation of AIF. Additionally, metformin-modulated apoptosis occurs via c-FLIP, downregulation, by facilitating the ubiquitin/proteasome-mediated pathway.

Materials and methods

Cell culture media and reagents

Human BC T24 cells were obtained from the American Type Culture Collection (Manassas, Virginia, USA). The BC cell line T24 were maintained in Roswell Park Memorial Institute (RPMI)1640 (Welgene, Kyungsan, Korea) medium, containing 10% fetal bovine serum (FBS; Welgene), 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES; Sigma, St. Louis, Missouri, USA) and 100 μg/ml gentamicin (Invitrogen, South San Francisco, California, USA) was used for the cell culture medium. Cells were cultivated at 37°C in a humidified atmosphere with 5% CO2. Metformin, N-acetylcysteine (NAC) and cycloheximide (CHX) were purchased from Sigma (Sigma). z-VAD-fmk and MG132 were obtained from Calbiochem (San Diego, California, USA).

Effect on cell morphology

T24 cells were treated with different concentrations of metformin (0, 3, 6, 9, 12 and 15 mM) for 24 h. They were also treated with metformin (12 and 15 mM) with/without inhibitors such as z-VAD-fmk, NAC for 24 h. The morphological changes were examined by an inverted microscope (magnification, ×200) (cat. no. DFC495; Leica, Wetzlar, Germany). The images were taken using the i-Solution program.

Cell viability assay

The XTT assay, performed using the WelCount cell proliferation assay kit (cat. no. TR055-01; WelGene), was used to determine cell viability. T24 cells were seeded at 2.5 × 104 cells/well in two 96-well plates containing RPMI1640 supplemented with 10% FBS. After treatment with metformin for 24 h, cells were incubated with XTT reagent working solution and mix well for 2 h at 37°C CO2 incubator. The working solution is produced by diluting 95% ethanol (cat. no. R4875; Sigma). The cells were further incubated at 37°C for 30 minutes. Cellular DNA was stained by incubating the cells with 250 μl propidium iodide (cat. no. P4170; Sigma) at 37°C for 30 minutes. To determine the relative DNA contents of the stained cells based on fluorescence-activated cell sorting (FACS) using the BD FACS Cato II flow cytometer (BD Biosciences, San Jose, California, USA).

Western blot analysis

T24 cell lysates were prepared by suspending 0.4 × 106 cells in 40 μl of lysis buffer consisting of 15 mM ethylene glycol tetraacetic acid (EGTA), 137 mM NaCl, 15 mM MgCl2, 0.1 mM sodium orthovanadate, 25 mM MOPS, 100 μM phenylmethanesulfonyl fluoride (PMSF), 0.1% Triton X-100 and 20 μM leupeptin (pH 7.2). The cells were disrupted by sonication, followed by protein extraction by incubating the samples at 4°C for 30 minutes. The total protein in the lysates was quantified by a using the bicinchoninic acid assay kit (Thermo Scientific, Waltham, Massachusetts, USA), according to the manufacturer’s instructions. The proteins (40 or 70 μg) were separated using 10 or 12% SDS PAGE gel and electrotransferred onto nitrocellulose membranes (GE Healthcare, Chicago, Illinois, USA). They were specifically detected by Immobilon Western Chemiluminescent HRP Substrate solution (Millipore, Darmstadt, Germany). They were detected using the Image Quant LAS 4000 Imaging System (GE Healthcare). The anti-PARP (1:1000) antibody was supplied by Cell Signaling Technology. The anti-caspase-3 (1:3000) and anti-c-FLIP (1:1000) antibodies were obtained from Enzo Life Sciences (Farmingdale, New York, USA). The anti-Bcl-2 (1:1000), anti-Mcl-1 (1:5000) and anti-actin (1:3000) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and anti-XIAP (1:5000) antibody was obtained from BD Biosciences.

RNA isolation and RT-PCR

c-FLIP, mRNA expression level was quantified via RT-PCR. Total RNA was extracted from T24 cells by the EasyBlue reagent (cat. no. 17061; Life Technologies, Korea). The cDNA was prepared using the M-MLV reverse transcriptase (cat. no. 18057018; Thermo Scientific), according to the manufacturer’s instructions. PCR primers were procured from GenoTech (Daejeon, Korea). GAPDH primer was used as a loading control. The primers used for the amplification on c-FLIP, and GAPDH were the following: c-FLIP: 5′-GGAGACATATAGAGTGCTGATGG-3′ and 5′-GATTATCAGGCAGATCTTCTAG-3′; GAPDH: 5′-AGTCTGGAGTCAACGGATTTG-3′ and 5′-GTTATGCGACTGACACTGTG-3′. PCR reaction was carried out using the following cycling conditions:
c-FLIP, : 94°C for 5 min, followed by 34 cycles of 94°C for 40 sec, 54°C for 45 sec and 72°C for 40 sec; GAPDH: 95°C for 5 min, followed by 24 cycles of 94°C for 30 sec, 58°C for 45 sec and 72°C for 40 sec and with last expansion at 72°C for 5 min. The PCR products were performed by 1.5% agarose gel electrophoresis and visualized with 10% ethidium bromide using a gel documentation system (cat. no. WGD30; DAIHAN, Korea).

**Measurement of apoptosis-inducing factor nuclear translocation**

The cells were harvested and washed three times with cold PBS, and then incubated with an extraction buffer consisting of HEPES 10 mM, sucrose 250 mM, KCl 10 mM, MgCl₂ 1.5 mM, EDTA 1 mM, EGTA 1 mM, digitonin 0.05% and PMSF 1 mM at 4°C for 10 min, then centrifuged at 10,000 g at 4°C for 10 min. The supernatant containing cytosolic proteins was removed and the pellet was incubated in a nuclear extraction buffer consisting of NaCl 350 mM, EDTA 1 mM, EGTA 1 mM, Tris–HCl 10 mM, pH 7.4 and protease inhibitors at 4°C for 20 min, and then centrifuged at 10,000 g at 4°C for 10 min. The proteins were loaded onto a 12% SDS-polyacrylamide gels and transferred on nitrocellulose membranes. After blocking in 5% skim milk at room temperature for 30 min, the membranes were probed with anti-AIF (1:1000), anti-α-tubulin (1:2000), and anti-lamin B (1:2000) antibodies, followed by incubation with a horseradish peroxidase-conjugated secondary antibody. Antibodies were procured from Santa Cruz Biotechnology (Santa Cruz, California, USA). The bands were detected by Immobilon Western Chemiluminescent HRP Substrate solution (Millipore Corporation, Bedford, Massachusetts, USA).

**Fig. 1**

Metformin induces apoptosis in T24 cells dose-dependently. (a) T24 cells were treated with the indicated concentration of metformin. After 24 h, cell viability was assessed using the XTT assay. (b) The morphological changes were examined by inverted microscope (magnification, ×200). (c) T24 cells were treated with metformin (0, 3, 6, 9, 12 and 15 mM) for 24 h. FACS analysis is shown in the upper panel. Apoptosis confirmed by flow cytometry is shown in the middle panel. Cell cycle phase is shown in the lower panel. (d) T24 cells were treated with metformin. PARP, cleaved-caspase-3 and β-actin expression levels were detected by western blot. β-actin was used as a control. Arrows indicate PARP and caspase-3 cleavage form. Data are representative from three independent experiments. The data are expressed as mean ± SD (n = 3). *P < 0.05 compared to non-treated cells. FACS, fluorescence-activated cell sorting.
Statistical analysis
Data were analyzed using one-way analysis of variance followed by posthoc comparisons using the Statistical Package for Social Sciences 8.0 (SPSS Inc., Chicago, Illinois, USA). All experiments were performed three independent times. The results were expressed as the mean ± SD and P values of less than 0.05 were considered to be statistically significant.

Results
Metformin induces apoptosis in human bladder cancer T24 cells
In our previous study, we reported that metformin mediated apoptosis in human renal cancer A498 cells [25]. To determine the apoptotic effects of metformin on the cell growth of human BC T24 cells, the cells were treated with different concentrations of metformin for 24 h. Our results showed that cell viability decreased in a dose-dependent manner in metformin-treated T24 cells (Fig. 1a). Next, we verified the apoptotic effects of metformin in T24 cells. As shown in Fig. 1b, treatment of T24 cells increased the typical characteristics of apoptosis, including cell shrinkage and detachment of cells from the culture vessel. The metformin-treated T24 cells caused a distinguishable and dose-dependent increase in sub-G1 phase cells (Fig. 1c). Additionally, treatment of T24 cells with metformin increased cleavage of PARP and cleaved-caspase3 (Fig. 1d). These results indicate that metformin induces a significant increase of apoptotic cells in the T24 cells dose-dependently.

Metformin suppresses the expression of c-FLIP_L proteins in T24 cells
To examine the underlying mechanism involved in metformin-induced apoptosis, we investigated the expression levels of various apoptotic-regulatory proteins by western blot. As shown in Fig. 2a, the c-FLIP_L protein levels were decreased in a dose-dependent manner in metformin-treated T24 cells. However, Bcl-2, Mcl-1 and XIAP protein levels were not altered in metformin-treated cells. Next, we analyzed whether the metformin-induced c-FLIP_L reduction was controlled at the transcriptional level. As shown in Fig. 2b, the c-FLIP_L mRNA level remained constant after treatment of T24 cells with metformin at various concentrations. Therefore, our results suggest that the metformin-induced reduction of c-FLIP_L protein levels is regulated at the post-transcriptional level.

Metformin-mediated apoptosis in T24 cells is partially blocked by inhibition of the caspase-dependent signaling pathway
We investigated whether the caspase signaling pathway played a role in metformin-induced apoptosis. As shown in Fig. 3a and b, metformin mediating cell viability, morphological changes apoptosis was partially inhibited by pretreatment with z-VAD-fmk, general caspase inhibitor, as revealed by XTT assay and microscopy. Sub-G1 population was partially prevented by treatment with z-VAD-fmk in the presence of metformin (Fig. 3c). In addition, treatment with z-VAD-fmk partially prevented the cleavage of caspase-3 and PARP, but not c-FLIP_L (Fig. 3d). These findings indicate that metformin-mediated apoptosis in BC cells is partially regulated by the caspase-dependent pathway.

Metformin-induced apoptosis in T24 cells is independent of reactive oxygen species levels
Reactive oxygen species (ROS) are a known key regulator of apoptosis [26]. To examine whether ROS played a role in metformin-induced apoptosis, T24 cells were pretreated with ROS scavenger, NAC for 30 minutes, and then treated with metformin for 24 h. NAC did not prevent metformin mediating cell viability, morphological changes and apoptosis in T24 cells (Fig. 4a–c). Moreover, NAC treatment failed to block the PARP cleavage, as well as activation of caspase and c-FLIP_L degradation in metformin-treated cells (Fig. 4d). The results showed...
Metformin induces apoptosis in T24 cells

Metformin-mediated apoptosis in T24 cells is partially blocked by inhibition of caspase-dependent signaling pathway. (a) T24 cells were pretreated with 50 μM z-VAD-fmk or a solvent for 30 minutes and incubated with 12 and 15 mM metformin for 24 h. Cell viability was assessed using the XTT assay. (b) T24 cells were incubated with 50 μM z-VAD-fmk or a vehicle for 30 min before treatment with metformin (12 and 15 mM). After 24 h, the morphological changes were examined using an inverted microscope (magnification, ×200). (c) Cells were pretreated with 50 μM z-VAD-fmk or a solvent for 30 minutes and incubated with 12 and 15 mM metformin for 24 h. The sub-G1 cell fraction was confirmed by flow cytometry. (d) T24 cells were treated with 50 μM z-VAD-fmk or a vehicle for 30 minutes before treatment with metformin for 24 h. PARP, cleaved-caspase-3, c-FLIP_L, and β-actin expression levels were detected by western blot. β-actin was used as a control. Arrows indicate PARP and caspase-3 cleavage form. Data are representative from three independent experiments. The data are expressed as mean ± SD (n = 3). *P < 0.05 compared to non-treated cells, #P < 0.01 compared with metformin-treated cells.

that ROS was not affected by metformin-induced apoptosis in T24 cells.

The metformin-mediated caspase-independent pathway is modulated by apoptosis-inducing factor translocation in T24 cells

To investigate the molecular mechanism of caspase-independent apoptosis, we examined the role of AIF in metformin-induced apoptosis. We detected AIF localization via western blot with fractioned cellular components. As shown in Fig. 5, metformin treatment induces AIF release in the cytosol and translocation to the nuclei. Moreover, AIF was found to be decreased in the mitochondria (Fig. 5). These findings suggest that metformin-mediated apoptosis in T24 cells is modulated by translocation of AIF from mitochondria to nucleus through the caspase-independent pathway.

Metformin-mediated c-FLIP_L protein degradation is regulated by the activation of the proteasomal signaling pathway in T24 cells

To further examine the underlying molecular mechanism of the decreased c-FLIP_L protein expression levels in metformin-treated cells, we performed a protein stability assay of c-FLIP_L. T24 cells were treated metformin in the absence or presence of CHX in order to obtain protein degradation kinetics. Our results revealed that c-FLIP_L protein degradation was facilitated by metformin treatment (Fig. 6a), implying that metformin treatment resulted in a decrease in the stability of the c-FLIP_L protein. Thus, we used a cell-permeable proteasome inhibitor, MG132, to identify the connection between c-FLIP_L protein levels and ubiquitin proteasome-mediated post-transcriptional regulation. The cells were pretreated MG132 for 1 h and then treated with metformin for 24 h. Our results showed that c-FLIP_L partially recovered metformin-induced
apoptosis in T24 cells treated with MG132 (Fig. 6b). These data suggest that metformin mediating apoptosis is modulated by downregulation of c-FLIP expression at the post-transcriptional level.

**Discussion**

In the present study, we showed that metformin exhibits meaningful anti-cancer activity against human BC cells. Moreover, we showed that metformin-induced apoptosis was regulated by both caspase-dependent and caspase-independent signaling pathways in human BC T24 cells. To our knowledge, this is the first study demonstrating that metformin mediated caspase-independent apoptosis occurs via nuclear translocation of AIF in T24 cells. Furthermore, we showed that metformin downregulated c-FLIP expression at the post-transcriptional level and that c-FLIP protein expression levels were downregulated by promoting protein degradation in metformin-treated cells.

Metformin is currently used to treat patients with type 2 diabetes [27]. Previous studies have reported that metformin shows a marked anticancer effect in several human cancer cell types, including cervical cancer, ovarian cancer and bile duct cancer through inhibition of cell proliferation, apoptosis, AMPK signaling and suppression of tumor growth [11,15,28]. However, the molecular mechanism of metformin in human BC cells has not yet been elucidated. Thus, we studied whether metformin had an anti-tumor effect on BC T24 cells. In our previous study, we proved that metformin-induced apoptosis caused the activation of caspase-3 and cleavage of PARP in the human renal cancer A498 cells [25]. Similarly, metformin stimulated the caspase-dependent apoptotic pathway in T24 cells dose-dependently, which was partially inhibited by treatment with the general caspase inhibitor, z-VAD-fmk. These results indicate that metformin-induced apoptosis is regulated by caspase-dependent and caspase-independent apoptotic signaling pathways.
Metformin induces apoptosis in T24 cells

Jang et al.

Fig. 6

Metformin-mediated apoptosis occurs via proteasomal signaling pathways in T24 cells. (a) Cells were treated with or without metformin 15 mM in the presence or absence of 20 μg/ml cycloheximide (CHX) for the indicated times. c-FLIP and β-actin expression levels were detected by western blotting. β-actin was used as a control for western blotting. (b) T24 cells were incubated with 0.5 μM MG132 or a vehicle for 1 h before treatment with metformin for 24 h. Data are representative from three independent experiments. The data are expressed as mean ± SD (n = 3). *P < 0.05 compared to non-treated cells, #P < 0.01 compared to metformin-treated cells. The c-FLIP density was analyzed by the ImageJ software.
The AIF protein is normally located in the outer membrane of the mitochondria and is translocated to the nucleus after activation of apoptotic pathways, where it involves in caspase-independent apoptotic events, such as chromatin condensation and DNA fragmentation [29,30]. In this study, we found that metformin treatment caused AIF release from the mitochondria followed by nuclear translocation in T24 cells, which indicates that metformin-mediated caspase-independent apoptosis is modulated by AIF translocation.

Previous studies have proved that c-FLIP_L expression is regulated at the ubiquitin proteasome-mediated post-transcriptional level or the transcriptional level [31,32]. Our results showed that metformin treatment did not alter c-FLIP_L mRNA expression. However, MG132 partially blocked metformin-mediated c-FLIP_L down-regulation. In addition, metformin promoted the ubiquitin/proteasome-mediated degradation of the c-FLIP_L protein, resulting in downregulation of c-FLIP_L. These findings suggest that the metformin-mediated decrease in c-FLIP_L expression was regulated at the post-transcriptional level.

In conclusion, this study is the first to demonstrate that metformin-induced apoptosis is mediated by caspase-dependent and caspase-independent signaling pathways through the activation of the AIF signaling pathway and increasing c-FLIP_L protein instability in human BC T24 cells. As such, we propose that metformin may be a potential candidate for novel anti-cancer drugs for BC.

Acknowledgements

This study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (grant no. 2017R1D1A1B3030961).

Conflicts of interest

There are no conflicts of interest.

References

1. Janković S, Radiosavljević V. Risk factors for bladder cancer. Tumour 2007; 93:4–12.
2. Grayson M. Bladder cancer. Nature 2017; 551:S33.
3. Bladder cancer: diagnosis and management of bladder cancer: (c) NICE (2013) Bladder cancer: diagnosis and management of bladder cancer. BJU Int 2017; 120:783–785.
4. Gadducci A, Biglia N, Tana R, Cosio S, Gallo M. Metformin use and gynecological cancers: a novel treatment option emerging from drug repositioning. Crit Rev Oncol Hematol 2016; 105:73–83.
5. Yan M, Gingras MC, Dunlop EA, Noetli Y, Dupuy F, Jaliat Z, et al. The tumor suppressor folliculin regulates AMPK-dependent metabolic transformation. J Clin Invest 2014; 124:2640–2650.
6. Laderoute KR, Calaogan JM, Madrid PB, Klon AE, Ehrlich PJ. SU11248 (sunitinib) directly inhibits the activity of mammalian 5'-AMP-activated protein kinase (AMPK). Cancer Biol Ther 2010; 10:68–76.
7. Yang F, Qin Y, Wang Y, Meng S, Xian H, Che H, et al. Metformin Inhibits the NLRP3 Inflammasome via AMPK/mTOR-dependent Effects in Diabetic Cardiomyopathy. Int J Biol Sci 2019; 15:1010–1019.
8. Aljošan M, Riehmacher D. Anticancer activity of metformin: a systematic review of the literature. Future Sci OA 2019; 5:FOS0410.
9. Lindsay C, Kostuk M, Conrad D, O’Connell DA, Harris J, Seikaly H, Biron VL. Antitumour effects of metformin and curcumin in human papillomavirus positive and negative head and neck cancer cells. Mol Carcinog 2019; 58:1946–1959.
10. Zakkhiani M, Dowling RJ, Soenenberg N, Pollak MN. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila) 2008; 1:369–375.
11. Kim MY, Kim YS, Kim M, Choi MY, Roh GS, Lee DH, et al. Metformin inhibits cervical cancer cell proliferation via decreased AMPK-O-GlcNAcylation. Anim Cells Syst (Seoul) 2019; 23:302–309.
12. Park JH, Kim YH, Park EH, Lee SJ, Kim H, Kim A, et al. Effects of metformin and phenformin on apoptosis and epithelial-mesenchymal transition in chemo-resistant rectal cancer. Cancer Sci 2019; 110:2834–2845.
13. Yudhahi RD, Astuli I, Mustola M, Indarto D, Muthmainah M. Metformin modulates cyclin D1 and P53 expression to inhibit nuclear proliferation and to induce apoptosis in cervical cancer cell lines. Asian Pac J Cancer Prev 2019; 20:1667–1673.
14. Ye J, Qi L, Chen K, Li R, Song S, Zhou C, Zhai W. Metformin induces TPC-1 cell apoptosis through endoplasmic reticulum stress-associated pathways in vitro and in vivo. Int J Oncol 2019; 55:331–339.
15. Lee J, Hong EM, Kim JH, Jung JH, Park SW, Koh DH, et al. Metformin induces apoptosis and inhibits proliferation through the AMP-Activated protein kinase and insulin-like growth factor 1 receptor pathways in the bilet duct cancer cells. J Cancer 2019; 10:1734–1744.
16. Zhou X, Liu S, Lin X, Xu L, Mao X, Liu J, et al. Metformin inhibit lung cancer cell growth and invasion in vitro as well as tumor formation in vivo partially by activating PP2A. Med Sci Monit 2019; 25:836–846.
17. Liang X, Kong P, Wang J, Xu Y, Gao C, Guo G. Effects of metformin on proliferation and apoptosis of human megakaryoblastic Dami and MEG-01 cells. J Pharmocol Sci 2017; 135:14–21.
18. Xiong ZS, Gong SF, Si W, Jiang T, Li OL, Wang TJ, et al. Effect of metformin on cell proliferation, apoptosis, migration and invasion in A172 glioma cells and its mechanisms. Mol Med Rep 2019; 20:867–894.
19. Bano D, Prehn JHM. Apoptosis-Inducing Factor (AIF) in Physiologe and Disease: the tale of a repented natural born killer. Ebiomedicine 2018; 30:29–37.
20. Sun H, Yang S, Li J, Zhang Y, Gao D, Zhao S. Caspase-independent cell death mediated by apoptosis-inducing factor (AIF) nuclear translocation is involved in ionizing radiation induced HepG2 cell death. Biochem Biophys Res Commun 2016; 472:137–143.
21. Bu Q, Wang J, Zheng Y, Zou Y, Wei M. MGL induces nuclear translocation of EndoG and AIF in caspase-independent T cell death. Cell Mol Biol Lett 2015; 20:816–824.
22. Soengas MS, Lowe SW. Apoptosis and melanoma chromoresilence. Oncogene 2003; 22:3138–3151.
23. Feng X, Shi Y, Xie L, Zhang K, Wang X, Liu Q, Wang P. 2-deoxy-D-glucose augments photodynamic therapy induced mitochondrial caspase-independent apoptosis and energy-mediated autophagy. Lasers Surg Med 2019; 51:352–362.
24. Benitez-Guzmán A, Arriaga-Pizana L, Morán J, Gutiérrez-Pabello JA. Endonuclease G takes part in AIF-mediated caspase-independent apoptosis in Mycobacterium bovis-infected bovine macrophages. Vet Res 2018; 49:69.
25. Jang JH, Song IH, Sung EG, Lee TJ, Kim JY. Metformin-induced apoptosis facilitates degradation of the cellular caspase 8 (FLICE)-like inhibitory protein through a caspase-dependent pathway in human renal cell carcinoma A498 cells. Oncol Lett 2018; 16:2030–2038.
26. Ding H, Han C, Guo D, Chin YW, Ding Y, Kinghorn AD, D'Ambrosio SM. Selective induction of apoptosis of human oral cancer cell lines by avocado extracts via a ROS-mediated mechanism. Nutr Cancer 2019; 61:348–355.
27. Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger JS, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2016; 164:740–751.
28. Zou G, Bai J, Li D, Chen Y. Effect of metformin on the proliferation, apoptosis, invasion and angiogenesis of pancreatic cancer cells. Exp Ther Med 2019; 18:2086–2094.
29. Pradelli LA, Berenato M, Ricci JE. Mitochondrial control of caspase-dependent and -independent cell death. Cell Mol Life Sci 2010; 67:1589–1597.
30. Cande C, Ceconi F, Dessen P, Kroemer G. Apoptosis-inducing factor (AIF): key to the conserved caspase-independent pathways of cell death? J Cell Sci 2002; 115:4727–4734.
31. Safa AR. c-FLIP, a master anti-apoptotic regulator. Exp Oncol 2012; 34:176–184.